Last Update: Mar 05, 2026 

 Regulatory Post-Marketing Surveillance to Assess Safety and Effectiveness in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea : a rPMS Study 

ClinicalTrials.gov Identifier: [NCT07243782](https://clinicaltrials.gov/ct2/show/NCT07243782)

 

Novartis Reference Number:CAIN457MKR01

 

 [See if you Pre-qualify](#trial-eligibility "See if you Pre-qualify") 

 All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation. 

 

##  Study Description 

Regulatory Post-Marketing Surveillance in hidradenitis suppurativa, pediatric plaque psoriasis and JIA treated with Cosentyx®(secukinumab) in Korea This post-marketing study is a multicenter, single-arm, prospective, observational study.

Cosentyx is prescribed within the scope of the approved indications for hidradenitis suppurativa, pediatric plaque psoriasis, enthesitis-related arthritis and juvenile psoriatic arthritis in the juvenile idiopathic arthritis category. The decision to treat patients with the drug will be made within current clinical practice and will be clearly distinguished from the decision to include patients in this investigation. No additional diagnostics or monitoring will be performed for this study beyond what is typically performed in clinical practice.



 

 Condition Hidradenitis Suppurativa, Pediatric Plaque Psoriasis, Juvenile Idiopathic Arthritis 

 

 Overall Status Recruiting 

 

 Number of Participants76

 

 

 Start Date Dec 22, 2025 

 

 Completion Date Jun 15, 2027 

 

 Gender All 

 

 Age(s) 6 Years - 100 Years (Child, Adult, Older Adult) 

 

 

 

##  Interventions 

Drug

### Secukinumab



This is a prospective observational study. There is no treatment allocation. The decision to initiate treatment will be based solely on clinical judgement.

 



 

 

 

##  Eligibility Criteria 

Inclusion Criteria:

Hidradenitis suppurativa:

1\. Adults 18 years of age and older with moderate to severe hidradenitis suppurativa who are or will be receiving Cosentyx within the scope of approved indication.  
2\. Patients who have agreed to participate in study (written informed consent)

Pediatric plaque psoriasis:

1\. Patients with moderate to severe plaque psoriasis between the ages of 6 and 18 years who are receiving or will receive Cosentyx within the scope of approved indication.  
2\. Patients with patient or guardian consent to participate in study (written informed consent)

Juvenile idiopathic arthritis:

1\. Enthesitis related arthritis and juvenile psoriatic arthritis in juvenile idiopathic arthritis category patients with enthesitis related arthritis and juvenile psoriatic arthritis in juvenile idiopathic arthritis category between the ages of 6 and 18 years and are receiving or will receive Cosentyx within the scope of approved indication.  
2\. Patients with patient or guardian consent to participate in study (written informed consent)

Exclusion Criteria:

1\. Patients who are contraindicated according to national prescribing information  
2\. Patients participating in other interventional clinical trials



 

 South Korea 

####  Novartis Investigative Site 

Recruiting

 Seoul,Seoul,06973,South Korea

 

 

 

 

 

 

 

 

 

##  Worldwide Contacts 

If the location of your choosing does not feature any contact detail, please reach out using the information below.

#### Novartis Pharmaceuticals

Phone: [ +41613241111](tel:+41613241111) 

Email: <novartis.email@novartis.com>